RGLS 4326

Drug Profile

RGLS 4326

Alternative Names: RGLS-4326

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regulus Therapeutics
  • Class Antisense oligonucleotides; MicroRNAs
  • Mechanism of Action MicroRNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autosomal dominant polycystic kidney disease

Most Recent Events

  • 07 Nov 2017 Regulus files an IND application with the US FDA for Autosomal-dominant polycystic kidney disease before November 2017
  • 02 Mar 2017 Regulus Therapeutics announces intention to submit IND to US FDA for Autosomal-dominant polycystic kidney disease by end of 2017
  • 06 Dec 2016 Preclinical trials in Autosomal-dominant polycystic kidney disease in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top